Clinical trials: Ischemia
Cerebral Ischemia, Cardiac Arrest
Neuroprotective Goal Directed Hemodynamic Optimization in Post-cardiac Arrest Patients
The primary objective of the Neuroprotect trial is to assess whether or not a new goal directed hemodynamic optimization strategy can reduce cerebral ischemia in post-cardiac arrest (CA) patients.
- Trial name
- NEUROPROTECT (NCT02541591)
- Testing
- Neuroprotective goal directed hemodynamic optimization, MAP > 65mmHg
- Where
- 2 sites in Belgium
- Volunteers
- 112 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Cardiovascular Disease, Cardiomyopathy
Statin Therapy for Ischemic and Nonischemic Cardiomyopathy
The purpose of this study is to see if taking a cholesterol lowering drug Lipitor (Atorvastatin Calcium)will increase the number of endothelial progenitor cells (EPC's) circulating in the blood of heart failure patients taking…
- Conditions
- Cardiovascular Disease, Cardiomyopathy, Heart Disease, Myocardial Disease
- Trial name
- NCT00701220
- Testing
- Atorvastatin Calcium
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Philip Binkley
Stroke
Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)
The purpose of the study is to determine whether desmoteplase is effective and safe in the treatment of patients with acute ischaemic stroke when given within 3 to 9 hours from onset of stroke symptoms.
- Trial name
- NCT00856661
- Testing
- Desmoteplase
- Where
- 152 sites in United States, Belgium and 12 more
- Volunteers
- 270 people
- Sponsor
- H. Lundbeck A/S
Cardiovascular Diseases
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
AMR101 (icosapent ethyl [ethyl-EPA]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) developed by Amarin Pharma Inc.
- Trial name
- REDUCE-IT (NCT01492361)
- Testing
- AMR101, Statin therapy
- Where
- 410 sites in United States, Australia and 9 more
- Volunteers
- 8,179 people
- Sponsor
- Amarin Pharma Inc.
Stroke, Ischemic Attack, Transient
Connected Health Blood Pressure Monitoring In Stroke and TIA Patients
The goal of this pilot project is to assess adherence with home blood pressure monitoring in hypertensive patients with a history of cerebral infarction and to determine if a social incentive improves adherence with monitoring.
- Trial name
- CHAMPS (NCT02450760)
- Testing
- Social incentive
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Pennsylvania
Reperfusion Injury, STEMI
Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events
The EMBRACE-STEMI trial was a Phase 2a prospective, multicenter, multinational randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, and efficacy of IV administered elamipretide (also…
- Trial name
- EMBRACE (NCT01572909)
- Testing
- Bendavia (MTP-131)
- Where
- 30 sites in United States, Germany and 2 more
- Volunteers
- 300 people
- Sponsor
- Stealth BioTherapeutics Inc.
Coronary Restenosis
Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis
The purpose of this study was to investigate the use of systemic intracoronary administration of albumin-bound paclitaxel, ABI-007, for the prevention and reduction of restenosis following de novo stenting or following…
- Trial name
- SNAPIST-III (NCT00124943)
- Testing
- Nanoparticle Paclitaxel
- Volunteers
- 112 people
- Sponsor
- Celgene Corporation
Heterozygous Familial Hypercholesterolemia, Coronary Artery Disease
Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease
The purpose of this study is to determine whether mipomersen safely and effectively lowers low-density lipoprotein cholesterol (LDL-C) in patients with Heterozygous Familial Hypercholesterolemia (HeFH) and coronary artery disease…
- Trial name
- RADICHOL II (NCT00706849)
- Testing
- mipomersen sodium
- Where
- 48 sites in United States, Canada
- Volunteers
- 124 people
- Sponsor
- Kastle Therapeutics, LLC
Hypertension, Hypercholesterolemia
Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients
The primary objective is to investigate the safety of Caduet (2.5 mg/5 mg, 2.5 mg/10 mg, 5 mg/5 mg or 5 mg/10 mg as dose of Amlodipine/Atorvastatin) during 52 weeks treatment period in Japanese patients with both of hypertension…
- Conditions
- Hypertension, Hypercholesterolemia, Angina Pectoris
- Trial name
- NCT01190007
- Testing
- Caduet
- Where
- 20 sites in Japan
- Volunteers
- 159 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Heart Failure, Myocardial Ischemia
METhotrexate Therapy Effects in the Physical Capacity of Patients With ISchemic Heart Failure (METIS Trial)
The aim of the study is to evaluate the efficacy of methotrexate to improve physical capacity in patients with symptomatic ischemic heart failure.
- Trial name
- METIS (NCT00759811)
- Testing
- Methotrexate
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Instituto de Cardiologia do Rio Grande do Sul
Heart Disease, Coronary, Chest Pain
The Computed Tomography-derived Fractional Flow Reserve STAT Trial
This study is designed to directly compare Standard Care and CT fractional flow reserve (CTFFR) for diagnosis of chest pain patients with definite coronary artery disease (CAD) on heart computed tomography (CT) scans.
- Conditions
- Heart Disease, Coronary, Chest Pain, Acute Coronary Syndrome
- Trial name
- CTFFR-STAT (NCT03263806)
- Testing
- CTFFR-Guided Group Management, SOC Group Management
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Corewell Health East
Acute Coronary Syndrome (ACS)
Safety Study of Apixaban in Recent Acute Coronary Syndrome
The purpose of this clinical research study is to determine whether apixaban will be safe in people who have recently had unstable angina or a heart attack.
- Trial name
- NCT00313300
- Testing
- Apixaban
- Where
- 151 sites in United States, Austria and 12 more
- Volunteers
- 1,741 people
- Sponsor
- Bristol-Myers Squibb
Coronary Artery Disease
The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)
The purpose of this study is to evaluate the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo atherosclerotic coronary artery lesions.
- Trial name
- PLATINUM LL (NCT01500434)
- Testing
- PROMUS Element Coronary Stent System, Aspirin, Thienopyridine
- Where
- 30 sites in United States, Australia and 5 more
- Volunteers
- 102 people
- Sponsor
- Boston Scientific Corporation
Stroke
Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)
This is a study in patients who recently had a brain attack (stroke) and in whom no clear cause of the stroke could be identified.
- Trial name
- NAVIGATE ESUS (NCT02313909)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic acid (Aspirin, BAY1019036)
- Where
- 454 sites in United States, Argentina and 29 more
- Volunteers
- 7,213 people
- Sponsor
- Bayer
Acute Ischemic Stroke
Reperfuse Ischemic Vessels With Endovascular Recanalization Device in JAPAN (RIVER JAPAN)
The main objective of this study is to document that the thrombectomy catheter (Rev-01) is effective and safe when used for revascularization in subjects with acute ischemic stroke within 8 hours of symptom onset who are…
- Trial name
- NCT01895634
- Testing
- Rev-01
- Where
- Japan
- Volunteers
- 49 people
- Sponsor
- Johnson & Johnson K.K. Medical Company
Coronary Artery Disease
PET MYOCARDIAL Blood Flow Comparison to Coronary CTA and CT-FFR
The broad, long-term objective of this pilot study is to develop an optimal, clinically usable, non-invasive evaluation of Coronary Artery Disease (CAD) in the setting of stable angina which provides both anatomic and functional…
- Trial name
- NCT05349084
- Testing
- PET-cCTA-cFFR
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Washington University School of Medicine
Coronary Artery Disease
RESOLUTE ONYX Post-Approval Study (Bifurcation Cohort)
To observe the continued performance of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in a real-world more-comer population.
- Trial name
- NCT03584464
- Testing
- Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
- Where
- 25 sites in United States, Belgium and 2 more
- Volunteers
- 205 people
- Sponsor
- Medtronic Vascular
Coronary Artery Disease
Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)
Subjects being evaluated for suspected or known Coronary artery Disease (CAD) based on signs and/or symptoms, will be invited to participate in the study.
- Trial name
- GadaCAD 2 (NCT01890434)
- Testing
- Gadobutrol (Gadavist, Gadovist, BAY86-4875)
- Where
- 24 sites in United States, Australia and 2 more
- Volunteers
- 478 people
- Sponsor
- Bayer
Hypoxic-Ischemic Encephalopathy, Brain Injury
Prospective Research in Infants With Mild Encephalopathy
A multicenter observational pilot study will be conducted to determine the natural history of infants with early diagnosis (≤ 6 hrs of age) of mild neonatal encephalopathy (NE) who are not qualified for therapeutic hypothermia.
- Conditions
- Hypoxic-Ischemic Encephalopathy, Brain Injury, Neonatal Seizure
- Trial name
- PRIME (NCT01747863)
- Testing
- Neurologic examination
- Where
- 7 sites in United States, Canada and 2 more
- Volunteers
- 63 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Dementia, Cognition Disorders
Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation
Patients will be screened at Intermountain Medical Center and at Intermountain-affiliated anticoagulation clinics in the Salt Lake City region. Patients with non-valvular atrial fibrillation will be considered for study.
- Conditions
- Dementia, Cognition Disorders, Cerebral Ischemic Events
- Trial name
- CAF (NCT03061006)
- Testing
- Dabigatran Etexilate, Warfarin
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Intermountain Health Care, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.